EPISODE · Jun 3, 2020 · 30 MIN
Controlling the Scientific Narrative: Randomized Controlled Trials and The Manipulation of “Control”
from New Books in Science · host New Books Network
Modern science uses the “randomized controlled trial”—whereby people are randomly allocated either the drug or a placebo—as a gold standard to find out whether a newly discovered drug works. In this podcast, Dr. Martin Edwards, a general practitioner and retired clinician affiliated to the University of London, discusses the British Medical Research Council’s exploitation of the term “controlled” to establish “controlled trials” as the gold standard for therapeutic evaluation. His discussion is an extension of his paper “Control and the Therapeutic Trial: Rhetoric and Experimentation in Britain, 1918-48,” which is published in Brill’s Clio Medica. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science
What this episode covers
Modern science uses the “randomized controlled trial”—whereby people are randomly allocated either the drug or a placebo—as a gold standard to find out whether a newly discovered drug works. In this podcast, Dr. Martin Edwards, a general practitioner and retired clinician affiliated to the University of London, discusses the British Medical Research Council’s exploitation of the term “controlled” to establish “controlled trials” as the gold standard for therapeutic evaluation. His discussion is an extension of his paper “Control and the Therapeutic Trial: Rhetoric and Experimentation in Britain, 1918-48,” which is published in Brill’s Clio Medica. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science
NOW PLAYING
Controlling the Scientific Narrative: Randomized Controlled Trials and The Manipulation of “Control”
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m